Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Losartan
Drug ID BADD_D01322
Description Losartan is an angiotensin II receptor blocker (ARB) used to treat hypertension.[L7423] Angiotensin-converting enzyme (ACE) inhibitors are used for a similar indication but are associated with a cough.[L7423] When patients with ACE inhibitor associated coughs are switched to ARBs like losartan, they have an incidence of cough similar to placebo or [hydrochlorothiazide].[L7423] Losartan is available as losartan potassium oral tablets as well as a combination tablet of losartan potassium and hydrochlorothiazide.[L7423,L7426] Patients taking losartan should have their renal function and potassium levels monitored.[L7423] Losartan was granted FDA approval on 14 April 1995.[L7423]
Indications and Usage May be used as a first line agent to treat uncomplicated hypertension, isolated systolic hypertension and left ventricular hypertrophy. May be used as a first line agent to delay progression of diabetic nephropathy. Losartan may be also used as a second line agent in the treatment of congestive heart failure, systolic dysfunction, myocardial infarction and coronary artery disease in those intolerant of ACE inhibitors.
Marketing Status Prescription; Discontinued
ATC Code C09CA01
DrugBank ID DB00678
KEGG ID D08146
MeSH ID D019808
PubChem ID 3961
TTD Drug ID D0DD0K
NDC Product Code Not Available
Synonyms Losartan | 2-Butyl-4-chloro-1-((2'-(1H-etrazol-5-yl) (1,1'-biphenyl)-4-yl)methyl)-1H-imidazole-5-methanol | DuP-753 | DuP 753 | DuP753 | MK-954 | MK 954 | MK954 | Cozaar | Losartan Potassium | Potassium, Losartan | Losartan Monopotassium Salt | Monopotassium Salt, Losartan | Salt, Losartan Monopotassium
Chemical Information
Molecular Formula C22H23ClN6O
CAS Registry Number 114798-26-4
SMILES CCCCC1=NC(=C(N1CC2=CC=C(C=C2)C3=CC=CC=C3C4=NNN=N4)CO)Cl
Chemical Structure
ADR Related Proteins Induced by Drug
ADR Term Protein Name UniProt AC TTD Target ID PMID
Capillary fragility increasedC-C motif chemokine 2P14844Not Available26156105
Capillary fragility increasedInterleukin-1 alphaP01583T1634026156105
Capillary fragility increasedInterleukin-10P29456Not Available26156105
Metabolic disorderCytochrome P450 2C9P11712T192449663807; 11434505; 9825828
ADRs Induced by Drug
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Paraesthesia17.02.06.005--
Parkinsonism17.01.05.0030.000049%Not Available
Pathogen resistance11.01.08.0490.000013%Not Available
Peripheral coldness24.04.03.006; 08.01.09.0100.000194%Not Available
Peritonitis07.19.05.004; 11.01.07.0070.000073%
Petechiae24.07.06.004; 23.06.01.003; 01.01.03.0020.000097%Not Available
Pharyngeal oedema23.04.01.016; 22.04.05.003; 10.01.05.0160.000073%Not Available
Pharyngitis07.05.07.004; 22.07.03.004; 11.01.13.003--
Phlebitis24.05.03.001; 12.02.01.0020.000049%
Photosensitivity reaction23.03.09.003--
Plasma cell myeloma16.23.02.004; 01.14.02.004--Not Available
Platelet count decreased13.01.04.001--
Platelet disorder01.08.03.0010.000073%Not Available
Pleural effusion22.05.02.002--
Pneumonia22.07.01.003; 11.01.09.003--Not Available
Pollakiuria20.02.02.0070.000121%
Polyneuropathy17.09.03.0120.000073%Not Available
Poor peripheral circulation24.04.03.0130.000073%Not Available
Pre-eclampsia20.01.08.002; 18.02.03.002; 24.08.07.0020.000049%Not Available
Premature baby18.04.02.001--Not Available
Proteinuria20.02.01.0110.000121%
Pruritus23.03.12.001--
Psoriasis23.03.14.002; 10.02.01.036--Not Available
Pulmonary congestion02.05.02.002; 24.03.08.001; 22.01.03.0020.000013%Not Available
Pulmonary embolism24.01.06.001; 22.06.02.001--Not Available
Pulmonary haemorrhage24.07.01.016; 22.02.04.0030.000019%
Pulmonary hypertension24.08.03.002; 22.06.01.001--
Pulmonary hypoplasia22.10.01.002; 03.16.01.0030.000013%Not Available
Pulmonary oedema02.05.02.003; 22.01.03.0030.000170%
Purpura24.07.06.005; 23.06.01.004; 01.01.04.003--
The 11th Page    First    Pre   11 12 13 14 15    Next   Last    Total 19 Pages